Five studies did not sufficiently disaggregate costs, so the information strength was reduced (Table 3) [15, 20, 23, 24, 27].
Most studies do not disaggregate costs into their components, making it difficult to target the source and predictors of high costs.
To maintain confidentiality over prices we did not present disaggregated costs.
When studies disaggregated costs, there were not clear and common categories for input or activity cost categories.
For the selected timeframe (1 40 years) and probabilistic analysis, model outputs included disaggregated costs, total costs, exacerbations, life-years and QALYs gained, and incremental cost-effectiveness ratios (ICERs).
Additionally, we disaggregated costs by care setting (inpatient or outpatient), cost type (drug-related or medical), and resource component (eg, hospital stay, physician visits, PICC placement).
It was assumed that longer treatment increases the average costs of treatment minus costs of gonadotropins proportionately, rather than costs of any specific procedures; disaggregated cost-of-treatment data were not available.
We imputed missing (disaggregated) costs, EQ-5D and HAQ data at each time point, following mi procedures in StataSE 12. Imputation took place in five cycles, the estimates from which were then pooled and calculated using Rubin's rules.
First, since costs and delivery methods vary greatly, the economic evaluation should at least list disaggregated costs, and should present separate values for the amount of each resource used and the cost of the resource, so that different audiences can tailor the cost estimates to their settings.
The latter is usually explored in economic evaluations, which are made more useful to decisionmakers by reporting disaggregated cost-consequence information.[ 82] The economic evaluation component (E2) assesses the value of an intervention based on cost-effectiveness ratios obtained from the analytic perspectives (e.g., healthcare system, societal).
